US › Healthcare

Roivant Sciences Ltd (ROIV)

US · Healthcare · Biotechnology

$34.59+3.81%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$2.5M
Revenue YoY
-66.7%
Net profit
$303.0M
Profit YoY
+246.7%
EPS
$0.00
EPS estimate
$-0.45
Net margin
12,023.6%

EPS came in at 0.00 against a street estimate of -0.45 — a beat of 100.0%.

Key statistics

Market cap
$24.07B
Forward P/E
0.0
P/B
5.41
Book value
$6.29
EPS (TTM)
$-0.54
52-week high
$37.00
52-week low
$10.90
50-day MA
$32.57
200-day MA
$26.42
Beta
1.13

Analyst view

Analysts rate Roivant Sciences Ltd a strong buy (9 buy, 1 hold, 0 sell out of 10) with an average price target of $38.91.

Shareholding

Insiders
21.44%
Institutions
76.32%

Largest institutional holders

FundStake
FMR Inc10.79%
Morgan Stanley - Brokerage Accounts7.17%
BlackRock Inc6.13%
Qvt Financial LP3.48%
UBS Group AG3.13%
Vanguard Capital Management, LLC2.86%
Vanguard Portfolio Management, LLC2.75%
State Street Corp2.24%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Roivant Sciences Ltd — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.